DEF: LivaNova Sets 2026 Annual Meeting Date, Proposes Director Elections

LivaNova PLC has announced its 2026 Annual General Meeting of Shareholders, scheduled for June 10, 2026, to elect directors, approve executive compensation, and ratify auditor appointments.

Summary

• LivaNova PLC is holding its 2026 Annual General Meeting (AGM) virtually on Wednesday, June 10, 2026.
• Shareholders of record as of April 13, 2026, are eligible to attend and vote.
• The meeting agenda includes the election of eleven directors, an advisory vote on executive compensation (Say on Pay), and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.
• Shareholders will also vote on resolutions to authorize the directors to allot shares and disapply pre-emption rights, and to approve share repurchase contracts and counterparties.
• The company is seeking shareholder approval for its UK directors' remuneration report and to receive and adopt the UK Annual Report and Accounts for the year ended December 31, 2025.
• Re-appointment of PwC-UK as the UK statutory auditor for 2026 is also on the agenda, along with authorizing directors to determine their remuneration.
• The filing details the company's corporate governance practices, executive compensation structure, and director qualifications.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, highlighting strong corporate governance practices and positive shareholder engagement, alongside a clear agenda for the upcoming AGM. The company's 2025 financial performance also shows positive trends.

Positives

• LivaNova is committed to good corporate governance, with many practices reflecting shareholder feedback.
• Ten of the eleven current directors are independent.
• The Board has a separate Chair and CEO structure.
• All Audit and Compliance Committee members are financially literate and considered audit committee financial experts.
• The company has a robust Code of Ethics and Business Conduct.
• Majority voting is used in uncontested director elections.
• Directors are required to hold meaningful equity ownership in the company.
• The company has engaged with a majority of its top 30 shareholders.
• Executive compensation is designed to align with shareholder interests and is performance-driven.
• The company achieved strong shareholder support for its Say on Pay proposals in 2025 (97%).
• The company's 2025 performance included a 10.7% increase in revenue and improved operating income.
• Key developments in 2025 included positive results from the OSPREY trial for obstructive sleep apnea and advancements in VNS Therapy for epilepsy and depression.

Negatives

• One director nominee, Vladimir Makatsaria, is not independent as he is the CEO.
• The company's 2025 compensation peer group excluded some companies due to acquisitions, requiring adjustments for consistency.
• Michael Hutchinson, former Chief Legal Officer, departed in January 2026 and forfeited his unvested equity awards.

Risks

• The company acknowledges that cybersecurity incidents could have a material adverse effect, and insurance may not fully cover costs.
• The company relies heavily on its supply chain, and cybersecurity incidents at suppliers could adversely impact operations.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• The company has no present intention to exercise the authority to allot shares or disapply pre-emption rights beyond satisfying options and other awards, but may consider other market transactions.

Future Outlook

The filing does not provide specific forward-looking financial guidance but outlines upcoming shareholder votes and company activities for the 2026 AGM, including director elections, compensation approvals, and auditor ratifications.

Management Comments

• LivaNova is committed to good corporate governance, which promotes the long-term interests of the Company's shareholders and strengthens Board and management accountability.
• The Board believes that it is in the best interest of the Company and its shareholders for the Board to make a determination on whether to separate or combine the roles of Chair and CEO based upon the Company's circumstances at any particular point in time.
• The CHCM Committee believes that the mix and design of the elements of the Company's compensation program are appropriate and incentivize executive officers and key employees to establish and achieve goals that benefit the Company and its shareholders over the long term.
• The CHCM Committee determined that the work performed by Pearl Meyer did not create any conflicts of interest.
• The CHCM Committee concluded that shareholders are supportive of the Company's current executive compensation program, and that the Company's executive compensation programs are performing as intended.

Industry Context

StockSavvy.ai notes that LivaNova's proxy statement reflects standard practices for a UK-domiciled, US-listed medical technology company, particularly concerning director elections, executive compensation disclosures, and auditor ratification. The detailed breakdown of compensation and governance structures aligns with regulatory requirements and investor expectations in the healthcare sector.

Corporate Governance

Related Party Transactions

• In fiscal year 2025, there were no related party transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K, and no such transactions are currently proposed.

Stakeholder Impact

• Shareholders: The proposals at the AGM directly impact shareholder rights, including director elections, executive compensation oversight, and capital allocation strategies.
• Employees: Executive compensation and human capital management policies are detailed, indicating a focus on employee engagement and talent development.
• Auditors: The ratification of PwC-U.S. and re-appointment of PwC-UK as statutory auditors ensures continued independent financial review.

Next Steps

• Shareholders to vote on the proposed resolutions at the 2026 Annual General Meeting on June 10, 2026.
• The company will continue to engage with shareholders on governance and compensation matters.
• The company will implement approved share repurchase contracts and potentially allot shares as authorized by shareholders.

Key Dates

Recommendation

The filing is primarily procedural, outlining the agenda for the upcoming Annual General Meeting and detailing corporate governance and executive compensation practices. While the company reported positive financial performance in 2025 and maintains strong governance, there are no new material business developments or significant changes in outlook that would warrant a buy or sell recommendation at this time. A 'hold' recommendation reflects the stable operational and governance status presented.

Keywords

LivaNova, AGM, Proxy Statement, Director Election, Executive Compensation, Auditor Ratification, Shareholder Meeting, Corporate Governance, Share Repurchase, Remuneration Report